Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1.
The breast cancer metastasis suppressor 1 (BRMS1) gene has been shown to suppress metastasis without affecting the growth of the primary tumor in mouse models. It has also been shown to suppress the metastasis of tumors derived from breast, melanoma, and, more recently, ovarian carcinoma (see ref 1). However, how BRMS1 exerts its metastasis suppressor function remains unknown. To shed light into its metastatic mechanism of action, the sensitive 2D-DIGE analysis coupled with MS has been used to identify proteins differentially expressed by either overexpressing (Mel-BRMS1) or silencing BRMS1 (sh635) in a melanoma cell line. After comparison of the protein profiles from WT, Mel-BRMS1, and sh635 cells, 79 spots were found to be differentially expressed. Mass spectrometry analysis allowed the unambiguous identification of 55 polypeptides, corresponding to 43 different proteins. Interestingly, more than 75% of the identified proteins were down-regulated in Mel-BRMS1 cells compared to WT. In contrast, all the identified proteins in sh635 cells extracts were up-regulated compared to WT. Most of the deregulated proteins are involved in cell growth/maintenance and signal transduction among other cell processes. Six differentially expressed proteins (Hsp27, Alpha1 protease inhibitor, Cofilin1, Cathepsin D, Bone morphogenetic protein receptor2, and Annexin2) were confirmed by immunoblot and functional assays. Excellent correlation was found between DIGE analysis and immunoblot results, indicating the reliability of the analysis. Available evidence on the reported functions of the identified proteins supports the emerging role of BRMS1 as negative regulator of the metastasis development. This work opens an avenue for the molecular mechanisms' characterization of metastasis suppressor genes with the aim to understand their roles.
Rivera
José
J
Signal Transduction Group, Structural Biology and Biocomputing Programme, Centro Nacional de Investigaciones Oncológicas, Melchor Fernández Almagro 3, E-28029 Madrid, Spain. jrivera@cnio.es
Megias
Diego
D
Bravo
Jerónimo
J
D052006:Bone Morphogenetic Protein Receptors, Type II / Q000096:biosynthesis; D002232:Carbocyanines; D002402:Cathepsin D / Q000096:biosynthesis; D002460:Cell Line; D045744:Cell Line, Tumor; D003627:Data Interpretation, Statistical; D015180:Electrophoresis, Gel, Two-Dimensional; D005456:Fluorescent Dyes; D006801:Humans; D008545:Melanoma / Q000378:metabolism / Q000556:secondary; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D020543:Proteome / Q000096:biosynthesis*; D040901:Proteomics; D034622:RNA Interference; D012097:Repressor Proteins; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
C410024:BRMS1 protein, human; D002232:Carbocyanines; D005456:Fluorescent Dyes; D009363:Neoplasm Proteins; D020543:Proteome; D012097:Repressor Proteins; C089187:cyanine dye 3; C085321:cyanine dye 5; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II; D002402:Cathepsin D